Clinical trials: Parkinson's Disease
Parkinson Disease, Parkinson's Disease
REQUIP (Ropinirole Hydrochloride) IR Long-Term Phase 4 Study
Ropinirole Hydrochloride (ROP) was granted approval for the treatment of Parkinson's Disease (PD) on 20 October 2006. ROP is expected to be used for a long term in clinical practice.
- Trial name
- NCT00485069
- Testing
- ROP, ROP+L-Dopa
- Where
- 22 sites in Japan
- Volunteers
- 123 people
- Sponsor
- GlaxoSmithKline
Parkinson Disease
The Study is Being Conducted to Evaluate the Safety and Efficacy of XJN010 Nasal Spray in Patients With Parkinson's Disease Experiencing Off Episodes
The study is being conducted to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of XJN010 Nasal Spray in Patients with Parkinson's Disease Experiencing Off Episodes
- Trial name
- NCT07156773
- Testing
- XJN010 Nasal Spray
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Guangzhou Novaken Pharm Co., Ltd.
Parkinson's Disease
Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease Subjects
Approximately twenty four (24) subjects will participate in this research trial. The research trial will be conducted in approximately twelve (12) medical centers in the following countries: Germany, France, South Africa, Austria…
- Trial name
- Safinamide-LID (NCT01113320)
- Testing
- Safinamide
- Where
- 11 sites in Austria, Canada and 3 more
- Volunteers
- 26 people
- Sponsor
- Newron Pharmaceuticals SPA
Parkinson's Disease
ADX48621 for the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's Disease
The primary objective of the study is to evaluate the safety and tolerability of ADX48621 in Parkinson's disease patients following four weeks of dosing.
- Trial name
- NCT01336088
- Testing
- ADX48621
- Where
- 25 sites in United States, Austria and 2 more
- Volunteers
- 83 people
- Sponsor
- Addex Pharma S.A.
Parkinson Disease
Safety, Tolerability and Efficacy of Switching From Talipexole to Pramipexole in Patients With Parkinson's Disease
Study to assess the safety, tolerability and effectiveness of a switching from Domin® (talipexole) tablet to BI Sifrol® (pramipexole) tablet in patients with Parkinson's disease
- Trial name
- NCT02231905
- Testing
- BI-Sifrol®
- Volunteers
- 29 people
- Sponsor
- Boehringer Ingelheim
Parkinson Disease
Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States:
Real-World Participants Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States: A Prospective, Phase 4, Multicenter, Observational Study in Parkinson's Disease
- Trial name
- NCT07219927
- Testing
- Observational study
- Where
- 5 sites in United States
- Volunteers
- 120 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Parkinson's Disease (PD)
Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide
The purpose of this study is to determine the effect of three single oral doses of nebicapone (50 mg, 100 mg and 200 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of controlled release…
- Trial name
- NCT02778594
- Testing
- BIA 3-202, levodopa 100 mg / benserazide 25 mg
- Where
- Portugal
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease (PD), Parkinson Disease 6, Early-Onset
Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of TJ0113 Capsules in Patients With Early-Onset Parkinson's Disease
This study is a randomized, double-blind, multicenter, placebo-controlled Phase III clinical trial designed to evaluate the efficacy, safety, and Pop PK characteristics of TJ0113 Capsules in treating EOPD patients.
- Trial name
- NCT07741045
- Testing
- TJ0113 200mg, TJ0113 400mg
- Where
- 21 sites in China
- Volunteers
- 300 people
- Sponsor
- Hangzhou PhecdaMed Co., Ltd.
Parkinson's Disease
Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Parkinson's Disease
This study is to evaluate the safety and efficacy of Umbilical Cord Derived Mesenchymal Stem Cells transplantation in Parkinson's disease.
- Trial name
- NCT03550183
- Testing
- mesenchymal stem cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Hebei Newtherapy BIo-Pharma technology Co., Ltd.
Idiopathic Parkinson's Disease
Stalevo in Early Wearing-Off Patients
The purpose of this study is to demonstrate in patients with Parkinson's disease that, when compared to levodopa/carbidopa, Stalevo will delay the time from initiation of study drug to the time an increase in antiparkinsonian…
- Trial name
- SEWOP (NCT00125567)
- Testing
- Stalevo (levodopa/carbidopa/entacapone), Levodopa/carbidopa
- Where
- 19 sites in Denmark, Finland and 4 more
- Volunteers
- 223 people
- Sponsor
- Orion Corporation, Orion Pharma
Parkinson's Disease
Evaluation of the Long-term Safety, Tolerability, and Efficacy of Perampanel (E2007) as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects With Motor Fluctuations
This is a multicentre, open-label extension study to evaluate the long-term safety, tolerability, and efficacy of Perampanel (E2007) as an adjunctive therapy in levodopa treated PD subjects with motor fluctuations.
- Trial name
- NCT00505622
- Testing
- Perampanel
- Where
- France
- Volunteers
- 328 people
- Sponsor
- Eisai Limited
Parkinson Disease(PD)
Adaptive DBS for PD
The goal of this clinical trial is to evaluate the efficacy and safety of an adaptive deep brain stimulation (aDBS) system for managing Parkinson's disease symptoms.
- Trial name
- SMART-DBS (NCT07635823)
- Testing
- adaptive deep brain stimulation, conventional deep brain stimulation
- Where
- 9 sites in China
- Volunteers
- 60 people
- Sponsor
- Beijing Pins Medical Co., Ltd
Parkinson Disease
Safety and Efficacy of Pramipexole and Bromocriptine Combined With L-dopa in Parkinson's Disease
The objective of the study was to evaluate the efficacy and safety of SND 919 (pramipexole) tablets administered in combination with L-dopa in patients with Parkinson's disease using placebo and bromocriptine tablets as…
- Trial name
- NCT02172573
- Testing
- Pramipexole, Bromocriptine
- Volunteers
- 315 people
- Sponsor
- Boehringer Ingelheim
Parkinson's Disease, Restless Leg Syndrome
A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Under Fed Conditions
The objective of this study was to assess the single dose bioequivalence of Roxane's Ropinirole tablets,0.25 mg, to ReQuip Tablets, 0.25 mg (GlaxoSmithKline) under fed conditions using a single dose, randomized, 2-treatment…
- Trial name
- NCT00674310
- Testing
- Ropinirole Hydrochloride
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Parkinson's Disease, Essential Tremor
Evaluation of Directional Recording and Stimulation Using spiderSTN
The purpose of this study is to provide proof-of-concept that directional stimulation and directional recording, in an intraoperative setting, is perceivable in a subject.
- Trial name
- NCT02894567
- Testing
- Intraoperative test during a deep brain stimulation surgery
- Where
- Switzerland
- Volunteers
- 6 people
- Sponsor
- Aleva Neurotherapeutics SA
Alzheimer Disease, Parkinson Disease
Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's Patients
Annovis is conducting a clinical study to investigate Posiphen in patients with Early Alzheimer's Disease (AD) and Early Parkinson's Disease (PD). Investigators are looking to recruit 68 patients in two parts of the study.
- Trial name
- NCT04524351
- Testing
- Posiphen
- Where
- 13 sites in United States
- Volunteers
- 75 people
- Sponsor
- Annovis Bio Inc.
Early Stage Parkinson's Disease
The Effects of Aplindore on the Treatment of Signs and Symptoms of Parkinson's Disease
The purpose of this study is to demonstrate the safety, tolerability, efficacy and pharmacokinetics of aplindore in patients with early stage Parkinson's Disease (PD) who are not currently taking any dopamine agonists or who are…
- Trial name
- NCT00623324
- Testing
- Aplindore
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Ligand Pharmaceuticals
Parkinson's Disease
An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advance-Stage Parkinson's Disease
The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of the Rotigotine patch in subjects with advanced-stage idiopathic Parkinson's Disease.
- Trial name
- SP715 (NCT00594386)
- Testing
- Rotigotine
- Where
- 41 sites in United States, Canada
- Volunteers
- 258 people
- Sponsor
- UCB Pharma
Parkinson's Disease
Single Ascending Dose Study of PRX002 in Healthy Subjects
This single ascending dose study is to determine safety, tolerability, pharmacokinetics and immunogenicity of PRX002 in approximately 40 healthy subjects.
- Trial name
- NCT02095171
- Testing
- PRX002
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Prothena Biosciences Limited
Parkinson Disease, Parkinson's Disease
An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease
To evaluate the safety profile of ropinirole XL during long-term treatment in subjects with early and advanced Parkinson's disease
- Trial name
- NCT00632736
- Testing
- Ropinirole XL (formerly CR)
- Where
- 75 sites in United States, Belgium and 7 more
- Volunteers
- 419 people
- Sponsor
- GlaxoSmithKline